Business Wire

UiPath launches a pro bono automation project with the Mater Hospital to free up nurses dealing with infection control including Covid-19

26.3.2020 15:00:00 EET | Business Wire | Press release

Share

Today UiPath is launching a pro bono automation project with the Mater Misericordiae University Hospital. The initiative will see software robots assigned to the Infection Prevention and Control (IPC) Department at the Mater. This development will significantly reduce the administrative strain placed upon the department by multidrug resistant organisms or viruses such as Covid-19, enabling IPC nurses to spend more time with patients. The project will see the Mater offered free trial robot licenses for the IPC Department until the end of the year.

With data being automated through software robots, the information will be processed in a fraction of the current time, disseminating patient results in minutes. It will save the infection control department 3 hours per day, 18 hours per week and 936 hours a year which they can now spend managing the current Covid-19 pandemic.

As a result of Covid-19, the Mater expects to receive hundreds of swabs and microbiology tests in the coming months which the software robots can assist in rapid processing. The results can then be distributed to healthcare workers rapidly and essential infection prevention and control measures can be put into action.

Jincy Jerry, Assistant Director of Nursing, Infection Prevention and Control, MMUH, said: “Given that IPC nurses spend close to 30% of their day with administrative tasks, for the past few months I have been looking at ways to make software robots part of our daily jobs. With the COVID-19 pandemic unfolding now, it is crucial that all frontline staff are freed up as much as possible to spend time with patients and deal with this outbreak, rather than being in front of computers.”

“Not only will automation help with this, but it will also take the strain off the hospital as it continues to process huge amounts of more routine patient data in addition to Covid-19 specific information.”

“As we’ve already seen, alongside the public playing their part in physical distancing, fast diagnosis and appropriate self-isolation are crucial to preventing the spread of COVID-19. We’re confident that the project we’re embarking on will help mitigate the huge strain this outbreak is putting on healthcare organisations – not just in MMUH, but across Ireland.”

Mark O’Connor, Public Sector Director Ireland at UiPath, said: “Infection Prevention & Control is critical to help people stay healthy, and while COVID-19 is top of mind, this project will continue to deliver benefits long term. At this time of heightened stress and anxiety, it’s vital to free up doctors and nurses’ time for patients wherever it can be done.”

“Robotic process automation minimises, if not removes, the need for people to carry out repetitive, rules-based admin work – speeding up processes and ensuring they’re error-free. With a robot for every nurse approach, essential frontline staff will be freed to be nurses and not system administrators, being able to focus more on the quality of care – which can make a real difference when it comes to treating patients in times of need.”

O’Connor will be hosting a webinar on April 2, 2020 at 10 a.m. EST/3 p.m. BST to discuss Mater’s use of automation to respond to Covid-19-related scenarios. To register, visit this link.

For more information on UiPath, go to uipath.com.

About UiPath

UiPath is leading the era of “Automation First” by betting on a robot for each person and allowing robots to learn new skills through artificial intelligence (AI) and machine learning (ML). Through free and open training, UiPath brings digital era skills to millions of people around the world, improving business productivity and efficiency, employee engagement, and customer experience.

The company’s hyper-automation platform combines the number one Robotic Process Automation (RPA) solution with a full suite of capabilities, including process mining and analytics, that enable every organization to scale digital business operations at unprecedented speed. The company has already automated millions of repetitive, mind-numbing tasks for businesses and government organizations all over the world, including more than 50% of the Fortune 500 and 8 of the Fortune 10.

UiPath has recently been recognised as the top company in The Deloitte Technology Fast 500 for 2019, a ranking of the fastest growing public and private technology companies in North America, and number 3 in the 2019 Forbes Cloud 100.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Toni Iafrate 
UiPath 
toni.iafrate@uipath.com
978-239-5499 

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye